KOREA WHO
-
-
-
CEO of HK inno.N
Kwak Dal-won
A Lifetime in Pharmaceuticals from CJ CheilJedang: Focus on Expanding Sales of New Drugs and IV Solutions
-
Last Updated on Nov 1, 2024
-
CEO of HK inno.N
Life Summary
Kwak Dal-won is the CEO and President of HK inno.N.
After CJ Healthcare was acquired by Korea Kolmar, its name was changed to HK inno.N.
HK inno.N aims to maximize corporate value by increasing sales abroad for treatments like ‘K-CAB,’ a medication for gastroesophageal reflux disease, while also expanding its health functional foods and Health & Beauty (H&B) business segments.
The company is also exploring new ventures, such as Contract Development and Manufacturing Organization (CDMO) services in biopharmaceuticals.
Kwak was born on May 13, 1960.
He graduated from Gyeongbok High School and earned a degree in business administration from Sungkyunkwan University, where he later obtained a master’s degree in marketing.
Kwak started his career at Samsung Group and later held various positions at CJ CheilJedang’s pharmaceutical division, including roles as Head of Yeongnam Regional Sales, Head of Sales Support, and Head of the Second Business Division.
When CJ CheilJedang’s pharmaceutical division became an independent company as CJ Healthcare, he served as Co-CEO. After the transition to a single-CEO system under Kang Seok-hee, Kwak led the Competitiveness Enhancement Task Force (TF).
Following CJ Healthcare’s acquisition by Korea Kolmar and its renaming to HK inno.N, Kwak served as Head of Prescription Drugs (ETC) and Head of Production before being appointed as CEO of HK inno.N in 2022.
After CJ Healthcare was acquired by Korea Kolmar, its name was changed to HK inno.N.
HK inno.N aims to maximize corporate value by increasing sales abroad for treatments like ‘K-CAB,’ a medication for gastroesophageal reflux disease, while also expanding its health functional foods and Health & Beauty (H&B) business segments.
The company is also exploring new ventures, such as Contract Development and Manufacturing Organization (CDMO) services in biopharmaceuticals.
Kwak was born on May 13, 1960.
He graduated from Gyeongbok High School and earned a degree in business administration from Sungkyunkwan University, where he later obtained a master’s degree in marketing.
Kwak started his career at Samsung Group and later held various positions at CJ CheilJedang’s pharmaceutical division, including roles as Head of Yeongnam Regional Sales, Head of Sales Support, and Head of the Second Business Division.
When CJ CheilJedang’s pharmaceutical division became an independent company as CJ Healthcare, he served as Co-CEO. After the transition to a single-CEO system under Kang Seok-hee, Kwak led the Competitiveness Enhancement Task Force (TF).
Following CJ Healthcare’s acquisition by Korea Kolmar and its renaming to HK inno.N, Kwak served as Head of Prescription Drugs (ETC) and Head of Production before being appointed as CEO of HK inno.N in 2022.